Niva Bupa Health Insurance Company Q1 FY27 earnings call

Niva Bupa reported robust Q1 FY27 results, with overall growth (reported basis) reaching 31.7% and retail health growth (reported basis) at an impressive 47.1%. The company's profit after tax (PAT) for the quarter stood at INR 137.8 crores. This strong performance contributed to a significant improvement in the combined insurance service ratio (CISR), which came in at 100.2%, down from 103.2% in Q1 last year.

The company continues to execute on its diversified multi-channel strategy, including the 'Bharat initiative' aimed at penetrating Tier 2 and Tier 3 towns. Management anticipates sustaining growth 8 to 10 percentage points faster than the market in retail health. Key growth enablers include the continuous expansion of the advisor network, successful new product launches such as Reassure 3.0, and the strategic adoption of AI-led capabilities to enhance operational productivity.

Niva Bupa demonstrated enhanced operational efficiency, with the expense of management (EoM) ratio improving to 35.2% in Q1 FY27 from 38% in the prior year's corresponding quarter. This provides a comfortable headroom of 100 basis points against the allowable EoM of 36.2%. The retail loss ratio also saw a positive trend, improving by 90 basis points to 67.5% in Q1, contributing to the overall CISR improvement. The company aims to stabilize the EoM ratio in the range of 32-33% going forward^⏳.

The Preferred Provider Network (PPN) strategy is yielding positive results, now encompassing over 1,000 hospitals across 49 cities, with 22% of claims flowing through these facilities. PPN helps reduce average claim sizes by 15-20% for secondary care treatments compared to tertiary setups, and improves claim ratios by ensuring appropriate care. Customer satisfaction also improved, with NPS scores rising to 62, and the claims settlement rate reaching 95.6% in Q1.

The board has approved a resolution to raise up to INR 500 crores in debt to support the company's growth plans, especially as an existing NCD of INR 250 crores is due this fiscal year. Niva Bupa maintains an AAA issuer rating from ICRA. The investment strategy remains conservative yet yield-focused, with an annualized investment yield of 7.2% in Q1. The company is also significantly investing in AIF segments, which offer 12-15% yields, currently representing 4% of its AUM.

The company noted ongoing industry-wide initiatives, including an awareness campaign with a collective annual spend of INR 120 crores, 50% of which is dedicated to health insurance. Niva Bupa has successfully transitioned to the Ind AS accounting standard for financial reporting. Furthermore, the health insurance committee is actively working on standardizing care pathways and position statements for various treatments, including infections, robotic surgeries, and oncology.